CureVac, in Germany, said on Wednesday that the final results of the trials showed that its coronavirus vaccine had an efficacy rate of only 48%, much lower than that developed by BioNTech / Pfizer mRNA rivals and Modern.
The result was expected after few provisional data were released earlier this month.
The company blamed, in part, the “unprecedented context of 15 strains circulating” among the trial volunteers, as well as the variable responses. age groups.
COVID vaccines developed by the German BioNTech in collaboration with the American giant Pfizer and the American firm Moderna, based on the same new messenger RNA technology, were previously approved in the pandemic after showing effectiveness of 95%.
His trials only had to fight the original strain of the virus. But recent studies indicate that both vaccines also offer strong protection against newer and more contagious variants.
CureVac said its punch, known as CVnCoV, worked slightly better among people aged 18 to 60 than among older ages, with an efficiency that rose to 53 percent.
Between the same age group of 18 to 60 years, the vaccine offered 100% protection against hospitalization and death.
In a statement, CEO Franz-Werner Haas said “CVnCoV demonstrates strong public health value” for people aged 18 to 60 “which we believe will be an important contribution to helping manage the COVID-19 pandemic and the propagation of the dynamic variant “.
“No security issues”
The CureVac phase 2b / 3 trial in the final phase involved about 40,000 people in 10 countries in Europe and Latin America. Of these, 228 contracted the coronavirus.
CureVac said in May that independent testing “found no safety issues” with its two-dose vaccine.
The Tuebingen-based company has shared its data with the European Medicines Agency (EMA), which will now decide whether the vaccine is good enough to be lit in green.
CureVac said it would give more details at a press conference on Thursday.
Its stock price fell nearly 10 percent in out-of-hours trading.
The European Union has secured up to 405 million doses of the CureVac vaccine if it receives regulatory approval.
Despite being a delay in the vaccine race, CureVac believes it has advantages over mRNA competitors.
The CureVac product can be stored at the standard refrigerator temperature, unlike first-generation Pfizer and Modern vaccines that require super-cold freezers.
The CureVac vaccine also requires a lower dose of only 12 micrograms, compared to 30 micrograms for BioNTech and 100 for Moderna, allowing for faster and cheaper mass production.
These factors could give CureVac an advantage in poorer or warmer countries.
2nd generation vaccine in development
Scientists have said that weaker-than-expected results can be reduced to the lowest dose, or even to the prescription of CureVac, which unlike its rivals uses an unmodified form of messenger RNA.
The company is already working on a second-generation COVID vaccine for which it has teamed up with pharmaceutical giant GSK.
Early results in rats have been promising, he said. Clinical trials in humans will begin in the third quarter of 2021.
CureVac was founded in 2000 by mRNA pioneer Ingmar Hoerr and is backed by Dietmar Hopp, the German billionaire behind the monstrous SAP software.
Last year the German government acquired a 23% stake in CureVac for 300 million euros.
The move came shortly after the media reported that President Donald Trump had sought exclusive U.S. access to any CureVac vaccine, a negative statement by both parties.
© 2021 AFP
Citation: Germany’s CureVac COVID vaccine is only 48% effective (2021, July 1), retrieved July 1, 2021 at https://medicalxpress.com/news/2021-07-covid-vaccine -germany-curevac-effective.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.